drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (engineered adoptive T cells)
drug_description
Adoptive T-cell therapy engineered to express membrane-anchored, tumor-targeted interleukin-12 (IL-12) to localize IL-12 signaling at the T-cell/tumor interface, drive Th1 activation, enhance CD8+ T-cell cytotoxicity and IFN-γ production, and modulate the tumor microenvironment.
nci_thesaurus_concept_id
C190860
nci_thesaurus_preferred_term
Cell Membrane-anchored/CSV-targeted IL-12-expressing T-lymphocytes
nci_thesaurus_definition
A preparation of T-lymphocytes engineered to express cell membrane-anchored and cell-surface vimentin (CSV)-targeted interleukin-12 (IL-12), with potential immunostimulatory and antineoplastic activities. Upon administration, the cell membrane-anchored/CSV-targeted IL-12-expressing T-lymphocytes are directed to and induce selective toxicity in CSV-expressing tumor cells. The cell membrane-anchored IL-12 cytokine promotes the secretion of interferon-gamma (IFNg), activates natural killer cells (NKs), and induces cytotoxic T-lymphocyte (CTL) responses against tumor cells locally, which may result in immune-mediated tumor cell death and the inhibition of tumor cell proliferation. Vimentin, overexpressed in various tumors, is associated with tumor growth and metastasis. Cell membrane-anchored IL-12 reduces the circulating levels of the inflammatory cytokine and the associated systemic adverse effects.
drug_mesh_term
Interleukin-12
drug_category
OTHER ENGINEERED IMMUNE CELL
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Engineered adoptive T cells expressing membrane-anchored, tumor-targeted interleukin-12 (IL-12) that localizes IL-12 signaling at the T cell–tumor interface via binding cell-surface vimentin (CSV). This drives Th1 polarization, enhances CD8+ T-cell cytotoxicity and IFN-gamma production, activates NK cells, and reprograms the tumor microenvironment to promote immune-mediated tumor cell killing while limiting systemic IL-12 exposure and toxicity.
drug_name
attIL12-T cells
nct_id_drug_ref
NCT05621668